Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening
2019 · Nature Cell Biology · 479 citations
https://doi.org/10.1038/s41556-019-0360-z
H
Hilde Brems
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
157
Papers
6.2K
Citations
37
h-index
63
i10-index
Hilde Brems is an academic researcher from Center for Human Genetics. The author has contributed to research in topics: Neurofibromatosis and Schwannoma Cases & Soft tissue tumors and treatment & Soft tissue tumor case studies. The author has an h-index of 37, co-authored 134 publications.
ORCID: 0000-0002-0325-4060Papers by this author
worksPRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies
2014 · Nature · 461 citations
https://doi.org/10.1038/nature13561
SVA retrotransposon insertion-associated deletion represents a novel mutational mechanism underlying large genomic copy number changes with non-recurrent breakpoints
2014 · Genome biology · 85 citations
https://doi.org/10.1186/gb-2014-15-6-r80
Examination of the genetic factors underlying the cognitive variability associated with neurofibromatosis type 1
2020 · Genetics in Medicine · 34 citations
https://doi.org/10.1038/s41436-020-0752-2
Keratinocytic epidermal nevus syndrome with Schwann cell proliferation, lipomatous tumour and mosaic KRAS mutation
2015 · BMC Medical Genetics · 29 citations
https://doi.org/10.1186/s12881-015-0146-5
Legius syndrome mutations in the Ras-regulator SPRED1 abolish its membrane localization and potentially cause neurodegeneration
2024 · Journal of Biological Chemistry · 5 citations
https://doi.org/10.1016/j.jbc.2024.107969
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat